Pay-for-delay deals declining, FTC report says
There have been more patent settlements involving generic drugs but fewer of them included provisions containing reverse payments, according to a Federal Trade Commission staff report.
The report stated during the...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch